Feng Mulin, Zeng Xiaohui, Li Jing
Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.
J Thorac Dis. 2019 Aug;11(8):3616-3625. doi: 10.21037/jtd.2019.06.35.
The efficacy of allergen immunotherapy (AIT) has been reported with different allergens including house dust mites (HDM). HDM are the most prevalent allergens in patients with asthma and/or rhinitis in China. In addition to improving symptoms, reducing medication need, and improving quality of life, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. To date, the use of AIT is becoming more acceptable in China, and there are many studies about the current clinical practice immunotherapy. In this paper we discuss the main aspects of AIT undertaken in China; including symptom and medication scores, pulmonary function and airway hyperresponsiveness, specific allergen sensitivity, safety evaluation, and mechanisms underlying AIT. This review will provide some important information on AIT treatment strategies to doctors, healthcare professionals and organizations involved in the AIT in China. According to the studies in China, successful AIT may induce antibody responses and cellular reactions in relation to the significant improvement in clinical symptoms, reducing the need for medications and maintenance of stable pulmonary functions.
变应原免疫疗法(AIT)对包括屋尘螨(HDM)在内的不同变应原已显示出疗效。在中国,HDM是哮喘和/或鼻炎患者中最常见的变应原。除了改善症状、减少药物需求和提高生活质量外,AIT还可以改变过敏性疾病的进程并诱导变应原特异性免疫耐受。目前,AIT在中国越来越被认可,并且有许多关于当前临床实践免疫疗法的研究。在本文中,我们讨论了中国开展的AIT的主要方面,包括症状和药物评分、肺功能和气道高反应性、特异性变应原敏感性、安全性评估以及AIT的潜在机制。本综述将为中国参与AIT的医生、医疗保健专业人员和组织提供有关AIT治疗策略的一些重要信息。根据中国的研究,成功的AIT可能会诱导抗体反应和细胞反应,这与临床症状的显著改善、药物需求的减少以及肺功能的稳定维持有关。